Sentence examples for difference in the cardiovascular from inspiring English sources

Magnussen et al. [ 17] did not find substantial difference in the cardiovascular risk factor profile between women who had experienced preterm and term PE.

It is interesting that in patients without metabolic syndrome this favorable effect was not presented: There was no significant difference in the cardiovascular end-points between bezafibrate and placebo groups.

In contrast, in patients without atherogenic dyslipidemia this favorable effect was absent: there was no significant difference in the cardiovascular end points between bezafibrate and placebo groups (for example, cardiac death was 7.7% vs. 7.7%).

The exception was the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS), which failed to show a significant difference in the cardiovascular event incidence between treated and placebo patients (6).

This discrepancy seems to be related to the difference in the cardiovascular risks of the patients in these studies compared to our study population (Table  2: diabetes duration 13 years, hypertension and dyslipidemia in 87.3% and smoking in 19% of the patients).

The present report targeted the assessment of differences in the cardiovascular risk profiles of subjects categorized differently as having or not having diabetes with diagnostic criteria based on plasma glucose and A1C.

Direct comparisons between the pretreatment and 2-hour posttreatment intervals (reported time peak of blood misoprostol levels) also revealed no significant differences in the cardiovascular index values.

Another limitation in this analysis is the differences in the cardiovascular definitions and comparators across studies.

Moreover, we demonstrated significant gender-dependent differences in the cardiovascular response to β-adrenoceptor stimulation.

Our findings suggest clinically important differences in the cardiovascular safety profiles of rosiglitazone and pioglitazone in clinical practice.

Sex differences in the cardiovascular system have largely been attributed to the effects of sex steroid hormones, such as estrogen and testosterone.